Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/11/2022* -- Results Q1 2022 -- -0.24 --
11/18/2021 -- Results Q4 2021 -0.20 -0.25 20.09%
08/16/2021 -- Results Q3 2021 -0.21 -0.28 25.27%
05/06/2021 -- Results Q2 2021 -0.36 -0.21 -68.99%
02/11/2021 -- Results Q1 2021 -0.20 -0.17 -21.00%
12/15/2020 -- Results Q4 2020 -0.17 -0.20 14.86%
08/06/2020 -- Results Q3 2020 -0.24 -0.36 32.83%
05/07/2020 -- Results Q2 2020 -0.44 -0.22 -103.9%
*Estimated Date/Time

Earnings

Next Report Date 02/11/2022
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/18/2021
Beat/Miss Upgrade
Return Since -34.00%
Last FQE 09/30/2021
Next FQE 12/30/2021

Profile

Edit
ESSA Pharma Inc is a pharmaceutical company. The company is in the preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
URL https://www.essapharma.com
Investor Relations URL https://investors.essapharma.com/
HQ State/Province British Columbia
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Feb. 11, 2022
Last Earnings Release Nov. 18, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio --
Cash Payout Ratio --
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
-48.47%
-89.99%
-52.12%
161.9%
116.9%
19.03%
-39.58%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-8.54%
-32.14%
-14.98%
115.7%
50.55%
197.1%
-31.74%
65.37%
-28.90%
-44.04%
-68.72%
-60.09%
-83.95%
-24.91%
3.66%
32.47%
-23.80%
47.27%
-31.65%
-37.82%
-81.28%
-95.69%
-49.88%
-74.05%
-20.17%
-59.29%
-4.23%
-63.31%
123.4%
107.8%
17.32%
103.1%
-15.85%
As of January 25, 2022.

Profile

Edit
ESSA Pharma Inc is a pharmaceutical company. The company is in the preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
URL https://www.essapharma.com
Investor Relations URL https://investors.essapharma.com/
HQ State/Province British Columbia
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Feb. 11, 2022
Last Earnings Release Nov. 18, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Stocktwits EPIX Tweets